Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. announced the granting of inducement awards to four new employees. These awards consist of options to purchase an aggregate of 115,250 shares of the Company's common stock. The options have grant dates of August 3, 2026 and August 6, 2026, and will vest over a four-year period, with full vesting by August 2030. The grants were made under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board of directors.

Cartesian Therapeutics reported a net income of $15.77 million for Q2 2026, or $0.47 per basic share, primarily driven by a $49.2 million gain on the change in fair value of contingent value rights liability. For the six months ended June 30, 2026, the company recorded a net loss of $23.41 million. The company also secured a new loan agreement with K2 HealthVentures for up to $150 million, having drawn $50 million by quarter-end, which is expected to fund operations for at least the next 12 months.

Cartesian Therapeutics reported a net income of $15.8 million for Q2 2026. The company extended its cash runway into 2028 with $149.3 million in cash, cash equivalents, and restricted cash, including $50 million from a new credit facility. Key pipeline updates include the Phase 3 AURORA trial data expected in 1Q27, a new strategic partnership with WestGene for an in vivo CAR-T platform, and progress in Phase 2 TRITON and Phase 1/2 HELIOS trials.

Cartesian Therapeutics provided an update on its clinical pipeline, announcing that Phase 3 AURORA trial data for Descartes-08 in myasthenia gravis (MG) is expected in 1Q27, with a BLA filing planned for mid-2027. The company also secured a strategic partnership with WestGene BioPharma to develop an in vivo CAR-T platform, with a Phase 1 trial expected to initiate in 2H26. Financially, Cartesian extended its cash runway into 2028 with $149.3 million in cash and up to $150 million in non-dilutive financing, supporting ongoing operations and precommercial readiness.

Cartesian Therapeutics, Inc. announced the granting of an inducement award to a new employee. On June 8, 2026, the company issued an option to purchase 6,100 shares of its common stock at an exercise price of $5.86 per share. This option, approved by the board of directors, vests 25% on June 8, 2027, and then in substantially equal monthly installments over the next three years, fully vesting by June 8, 2030. The award was granted under Nasdaq Listing Rules as a material inducement for the employee's entry into employment.

Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to advance novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases. The partnership integrates Cartesian's mRNA payload from Descartes-08 with WestGene's targeted lipid nanoparticle (LNP) platform, aiming to eliminate ex vivo manufacturing. A Phase 1 dose-escalation study for generalized myasthenia gravis is expected to initiate in 2H 2026, with clinical data anticipated in 1H 2027. WestGene will receive an upfront payment and potential milestone payments.

Cartesian Therapeutics, Inc. secured a Loan and Security Agreement for up to $150.0 million from K2 HealthVentures, with an initial $50.0 million tranche funded. This financing is expected to extend the company's cash runway into 2028 and support the advancement of multiple clinical programs. The company also provided updated timelines for its Descartes-08 clinical trials, including Phase 3 AURORA data in 1Q27, Phase 2 TRITON data in 1H27, and Phase 1/2 HELIOS data in 1H27. Additionally, the Chief Medical Officer, Miloš Miljković, will step down for personal reasons.

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche already funded. This financing is expected to extend the company's cash runway into 2028 and support the advancement of multiple clinical programs. The company also provided updated timelines for its Descartes-08 trials, including topline data from the Phase 3 AURORA trial in myasthenia gravis expected in 1Q27, and data from Phase 2 TRITON (myositis) and Phase 1/2 HELIOS (JDM) trials expected in 1H27. Additionally, Chief Medical Officer Miloš Miljković will be stepping down for personal reasons.

Cartesian Therapeutics, Inc. announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation is scheduled for Tuesday, May 19, 2026, at 3:00 p.m. ET, with a live webcast and archived replay available on the company's website. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases, with its lead asset Descartes-08 in various clinical development phases.

Cartesian Therapeutics, Inc. announced the granting of inducement awards to five new employees on May 1, 2026. These awards include options to purchase an aggregate of 317,200 shares of common stock at an exercise price of $6.22 per share. The options, approved by the board, will vest over four years, with full vesting by May 1, 2030, and have a ten-year term.